PLX-4720 is primarily used in research settings to study its effects on cancer cells, particularly those with the BRAF V600E mutation. This mutation is commonly found in melanoma and other cancers. The compound acts as a selective inhibitor of the mutated BRAF protein, which plays a critical role in cell growth and proliferation. By blocking this protein, PLX-4720 helps to halt the uncontrolled growth of cancer cells. It serves as a valuable tool in preclinical studies to understand the mechanisms of BRAF inhibition and to evaluate potential therapeutic strategies for BRAF-mutated cancers. Additionally, it aids in the development of targeted therapies and combination treatments to improve outcomes for patients with these specific genetic alterations.